Traditionally, small pharmaceutical or biotech companies, often limited by resources, tend to rely on FSPs or CROs for statistical programming and analytics support. The emergence and maturation of enterprise-caliber open-source software and tools present new and transformative opportunities for these organizations by helping to enhance data accessibility, streamline analysis workflows, and foster collaborative innovation. However, building these types of infrastructure within small pharma involves navigating budget constraints, limited IT resources, stakeholder buy-in and the need for specialized expertise. Overcoming these challenges requires strategic planning, prioritization, and training. This presentation will delve into the practical aspects and lessons learned from our experience of building up open-source technologies, such as the Posit computing environment, from scratch within the Clinical Development department at Recursion. By tackling these infrastructural hurdles, the integration of open-source toolsets has significantly improved our data analysis capabilities, accelerating drug development and positioning our company at the forefront of pharmaceutical innovation.
Chendi Liao
Recursion
Building Rome in a month: How open-source technologies empower small pharma
Traditionally, small pharmaceutical or biotech companies, often limited by resources, tend to rely on FSPs or CROs for statistical programming and analytics support. The emergence and maturation of enterprise-caliber open-source software and tools present new and transformative opportunities for these organizations by helping to enhance data accessibility, streamline analysis workflows, and foster collaborative innovation. However, building these types of infrastructure within small pharma involves navigating budget constraints, limited IT resources, stakeholder buy-in and the need for specialized expertise. Overcoming these challenges requires strategic planning, prioritization, and training. This presentation will delve into the practical aspects and lessons learned from our experience of building up open-source technologies, such as the Posit computing environment, from scratch within the Clinical Development department at Recursion. By tackling these infrastructural hurdles, the integration of open-source toolsets has significantly improved our data analysis capabilities, accelerating drug development and positioning our company at the forefront of pharmaceutical innovation.